Drug Detail

Drug Name Rebastinib
Trade Name
Synonyms DCC-2036
Drug Descriptions

Rebastinib (DCC-2036) inhibits BCR-ABL1 and ABL1 mutations including T315I, and has some activity against TIE-2, FLT3, and VEGFR2, potentially resulting in decreased tumor cell growth (PMID: 21481795).

DrugClasses BCR-ABL Inhibitor 24 FLT3 Inhibitor 50 TIE2 Inhibitor 1 VEGFR2 Inhibitor 34

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Therapy Name Drugs Efficacy Evidence Clinical Trials
Carboplatin + Rebastinib Carboplatin Rebastinib 0 1
Eribulin + Rebastinib Eribulin Rebastinib 0 1
Paclitaxel + Rebastinib Paclitaxel Rebastinib 0 2
Rebastinib Rebastinib 1 0


Additional content available in CKB BOOST